DK1296711T3 - HPV-E7 til behandling af humant papillomavirus - Google Patents
HPV-E7 til behandling af humant papillomavirusInfo
- Publication number
- DK1296711T3 DK1296711T3 DK01950461T DK01950461T DK1296711T3 DK 1296711 T3 DK1296711 T3 DK 1296711T3 DK 01950461 T DK01950461 T DK 01950461T DK 01950461 T DK01950461 T DK 01950461T DK 1296711 T3 DK1296711 T3 DK 1296711T3
- Authority
- DK
- Denmark
- Prior art keywords
- subject
- type
- papilloma virus
- human papilloma
- hpv
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6043—Heat shock proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21420200P | 2000-06-26 | 2000-06-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1296711T3 true DK1296711T3 (da) | 2006-08-28 |
Family
ID=22798190
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK01950461T DK1296711T3 (da) | 2000-06-26 | 2001-06-26 | HPV-E7 til behandling af humant papillomavirus |
Country Status (27)
Country | Link |
---|---|
US (4) | US20020110566A1 (da) |
EP (1) | EP1296711B1 (da) |
JP (1) | JP2004512264A (da) |
KR (2) | KR20080075560A (da) |
CN (1) | CN100441223C (da) |
AT (1) | ATE326236T1 (da) |
AU (3) | AU7144901A (da) |
BR (1) | BR0111956A (da) |
CA (1) | CA2413543A1 (da) |
CY (1) | CY1105389T1 (da) |
CZ (1) | CZ20024154A3 (da) |
DE (1) | DE60119734T2 (da) |
DK (1) | DK1296711T3 (da) |
EE (1) | EE200200709A (da) |
ES (1) | ES2263637T3 (da) |
HR (1) | HRP20021015A2 (da) |
HU (1) | HUP0301308A3 (da) |
IL (1) | IL153474A0 (da) |
MX (1) | MXPA02012858A (da) |
NO (1) | NO20026044L (da) |
NZ (1) | NZ523408A (da) |
PL (1) | PL359930A1 (da) |
PT (1) | PT1296711E (da) |
RU (1) | RU2282461C2 (da) |
SK (1) | SK18362002A3 (da) |
WO (1) | WO2002000242A2 (da) |
ZA (1) | ZA200210211B (da) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL105554A (en) * | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US20050244434A1 (en) * | 1999-08-12 | 2005-11-03 | Cohen David I | Tat-based tolerogen compositions and methods of making and using same |
US20050226890A1 (en) * | 1999-08-12 | 2005-10-13 | Cohen David I | Tat-based vaccine compositions and methods of making and using same |
US20050100928A1 (en) * | 1999-09-16 | 2005-05-12 | Zycos Inc., A Delaware Corporation | Nucleic acids encoding polyepitope polypeptides |
US8128922B2 (en) | 1999-10-20 | 2012-03-06 | Johns Hopkins University | Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen |
IL153474A0 (en) * | 2000-06-26 | 2003-07-06 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
AU2001278117A1 (en) | 2000-08-03 | 2002-02-18 | Johns Hopkins University | Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen |
WO2006033665A1 (en) * | 2004-03-16 | 2006-03-30 | Inist Inc. | Tat-based vaccine compositions and methods of making and using same |
WO2002062959A2 (en) | 2001-02-05 | 2002-08-15 | Stressgen Biotechnologies Corp. | Hepatitis b virus treatment |
US6649402B2 (en) * | 2001-06-22 | 2003-11-18 | Wisconsin Alumni Research Foundation | Microfabricated microbial growth assay method and apparatus |
AU2003284239B2 (en) * | 2002-10-21 | 2008-08-21 | Eisai Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
WO2004056389A1 (en) * | 2002-12-20 | 2004-07-08 | Glaxosmithkline Biologicals Sa | Hpv-16 and -18 l1 vlp vaccine |
EP1644048B1 (en) | 2003-05-05 | 2015-04-29 | Johns Hopkins University | Anti-cancer dna vaccine employing plasmids encoding signal sequence, mutant oncoprotein antigen, and heat shock protein |
WO2005026375A2 (en) | 2003-05-22 | 2005-03-24 | Fraunhofer Usa, Inc. | Recombinant carrier molecule for expression, delivery and purification of target polypeptides |
DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
US7285386B2 (en) * | 2003-10-29 | 2007-10-23 | University Of New Mexico, And Educational Institution Of The State Of New Mexico | RhPV as a model for HPV-induced cancers |
DE10357677A1 (de) * | 2003-12-10 | 2005-07-14 | Greiner Bio-One Gmbh | Primer und Sonden zum Nachweis genitaler HPV-Genotypen |
CA2594040A1 (en) | 2005-01-06 | 2006-07-13 | The Johns Hopkins University | Rna interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by dna and transfected dendritic cell vaccines |
US8252893B2 (en) * | 2005-01-31 | 2012-08-28 | Board Of Trustees Of The University Of Arkansas | CD8 T cell epitopes in HPV 16 E6 and E7 proteins and uses thereof |
ES2363247T3 (es) * | 2005-04-27 | 2011-07-28 | Leiden University Medical Center | Tratamiento para neoplasias intraepiteliales anogenitales inducidas por vph. |
WO2007117264A2 (en) * | 2005-08-03 | 2007-10-18 | Fraunhofer Usa, Inc. | Compositions and methods for production of immunoglobulins |
US7622121B2 (en) * | 2005-09-21 | 2009-11-24 | New York University | Heat shock proteins from Mycobacterium leprae and uses thereof |
WO2008048344A2 (en) * | 2006-02-13 | 2008-04-24 | Fraunhofer Usa, Inc. | Bacillus anthracis antigens, vaccine compositions, and related methods |
US8124103B2 (en) * | 2006-02-13 | 2012-02-28 | Fraunhofer Usa, Inc | Influenza antigens, vaccine compositions, and related methods |
WO2007095320A2 (en) * | 2006-02-13 | 2007-08-23 | Fraunhofer Usa, Inc. | Hpv antigens, vaccine compositions, and related methods |
JP2009538836A (ja) * | 2006-05-31 | 2009-11-12 | ヌベンタ バイオファーマシューティカルズ コーポレイション | 生物活性の精製HspE7組成物 |
US9085638B2 (en) | 2007-03-07 | 2015-07-21 | The Johns Hopkins University | DNA vaccine enhancement with MHC class II activators |
WO2008124483A1 (en) * | 2007-04-04 | 2008-10-16 | Specigen, Inc. | Protein cage immunotherapeutics |
WO2008134643A2 (en) * | 2007-04-28 | 2008-11-06 | Fraunhofer Usa, Inc. | Trypanosoma antigens, vaccine compositions, and related methods |
CA2692933C (en) | 2007-07-11 | 2016-10-18 | Fraunhofer Usa, Inc. | Yersinia pestis antigens, vaccine compositions, and related methods |
CN101820903A (zh) * | 2007-08-20 | 2010-09-01 | 美国弗劳恩霍夫股份有限公司 | 预防性和治疗性流感疫苗、抗原、组合物和方法 |
US20090117140A1 (en) * | 2007-09-26 | 2009-05-07 | Mayumi Nakagawa | Human papilloma virus dominant CD4 T cell epitopes and uses thereof |
US8877201B2 (en) * | 2007-10-25 | 2014-11-04 | Wake Forest University Health Sciences | Bordetella outer-membrane protein antigens and methods of making and using the same |
JP2011513399A (ja) | 2008-03-03 | 2011-04-28 | ザ ユニバーシティー オブ マイアミ | 同種癌細胞による免疫療法 |
AU2009226077B2 (en) | 2008-03-20 | 2012-04-19 | University Of Miami | Heat shock protein gp96 vaccination and methods of using same |
US8734803B2 (en) | 2008-09-28 | 2014-05-27 | Ibio Inc. | Humanized neuraminidase antibody and methods of use thereof |
WO2010049481A1 (en) * | 2008-10-31 | 2010-05-06 | Novartis Ag | Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor |
ES2621141T3 (es) * | 2008-11-28 | 2017-07-03 | Novartis Ag | Combinación farmacéutica que comprende un inhibidor de Hsp 90 y un inhibidor de mTOR |
ES2432863T3 (es) | 2009-03-23 | 2013-12-05 | Pin Pharma, Inc. | Tratamiento del cáncer con polipéptidos inmunoestimuladores derivados de Tat del VIH |
WO2011041391A1 (en) | 2009-09-29 | 2011-04-07 | Fraunhofer Usa, Inc. | Influenza hemagglutinin antibodies, compositions, and related methods |
US11963716B2 (en) | 2010-07-19 | 2024-04-23 | Emblation Limited | Apparatus and method for the treatment of dermatological diseases or conditions |
US9662510B2 (en) | 2010-07-19 | 2017-05-30 | Emblation Limited | Apparatus and method for the treatment of dermatological diseases or conditions |
CA2828443A1 (en) * | 2011-02-23 | 2012-08-30 | University Of Miami | Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv |
US9028884B2 (en) | 2013-08-13 | 2015-05-12 | Preventamedics LLC | Medical delivery devices and methods for applying a barrier composition to a targeted skin surface |
CA2926221A1 (en) | 2013-10-04 | 2015-04-09 | Pin Pharma, Inc. | Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment |
GB2541749B (en) | 2015-08-31 | 2020-12-09 | Emblation Ltd | An interference suppression apparatus and method |
US11497926B2 (en) | 2016-08-08 | 2022-11-15 | Emblation Limited | Method and apparatus for the treatment, management and/or control of pain |
EP3606550A2 (en) * | 2017-04-03 | 2020-02-12 | Neon Therapeutics, Inc. | Protein antigens and uses thereof |
CN108409866A (zh) * | 2018-01-23 | 2018-08-17 | 合肥瑞城生生物科技有限公司 | 一种用于治疗和预防人乳头瘤病毒感染及相关疾病的多表位组合肽 |
KR20210044805A (ko) * | 2018-08-06 | 2021-04-23 | 닐슨 바이오사이언스, 아이엔씨. | 사마귀의 치료 |
CN114478712B (zh) * | 2022-03-29 | 2022-09-23 | 深圳吉诺因生物科技有限公司 | Hpv抗原表位及其鉴定方法、应用 |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666847A (en) | 1981-01-16 | 1987-05-19 | Collaborative Research, Inc. | Recombinant DNA means and method |
NO172595C (no) | 1983-02-07 | 1993-08-11 | Battelle Memorial Institute | Fremgangsmaate og ekspresjonsplasmid for fremstilling av hemagglutinin under kontroll av drosophila hsp-promoter |
US4797359A (en) | 1983-05-10 | 1989-01-10 | Board Of Regents, The University Of Texas System | Heat shock regulated production of selected and fused proteins in yeast |
GB8404280D0 (en) | 1984-02-17 | 1984-03-21 | Stanford J L | Biological preparations |
IL71683A0 (en) | 1984-04-27 | 1984-09-30 | Yeda Res & Dev | Pharmaceutical compositions for treating arthritis type diseases comprising fractions obtained from mycobacteria |
US4918164A (en) | 1987-09-10 | 1990-04-17 | Oncogen | Tumor immunotherapy using anti-idiotypic antibodies |
US4784941A (en) | 1985-04-08 | 1988-11-15 | Genetic Systems Corporation | Expression and diagnostic use of pENV-3 encoded peptides which are immunologically reactive with antibodies to LAV |
DK3687A (da) | 1986-01-06 | 1987-07-07 | Hoffmann La Roche | Polypeptider og fremgangsmaade til fremstilling deraf |
US4734362A (en) | 1986-02-03 | 1988-03-29 | Cambridge Bioscience Corporation | Process for purifying recombinant proteins, and products thereof |
US4906742A (en) | 1986-07-31 | 1990-03-06 | Whitehead Institute For Biomedical Research | Encoding antigens of M. Leprae |
US6007806A (en) | 1986-08-13 | 1999-12-28 | Transgene S.A. | Expression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumor |
NL8701163A (nl) | 1986-09-09 | 1988-04-05 | Nederlanden Staat | Gebruik van een peptide voor de bereiding van preparaten voor het verlichten, het behandelen en de diagnose van autoimmuunziekten, in het bijzonder arthritische toestanden, verbindingen die met dit peptide verwant zijn, alsmede farmaceutische en diagnostische preparaten en testkits. |
WO1988005823A2 (en) | 1987-02-02 | 1988-08-11 | Whitehead Institute For Biomedical Research | Mycobacterium tuberculosis genes encoding protein antigens |
US4952395A (en) | 1987-02-26 | 1990-08-28 | Scripps Clinic And Research Foundation | Mycobacterial recombinants and peptides |
US5504005A (en) | 1987-03-02 | 1996-04-02 | Albert Einstein College Of Medicine Of Yeshiva University | Recombinant mycobacterial vaccine |
US4918166A (en) | 1987-04-10 | 1990-04-17 | Oxford Gene Systems Limited | Particulate hybrid HIV antigens |
US5256767A (en) | 1987-06-10 | 1993-10-26 | The Immune Response Corporation | Retroviral antigens |
NL8703107A (nl) | 1987-12-22 | 1989-07-17 | Nederlanden Staat | Polypeptiden en derivaten daarvan, alsmede de toepassing daarvan in farmaceutische en diagnostische preparaten. |
US5204259A (en) | 1988-05-06 | 1993-04-20 | Pharmacia Genetic Engineering, Inc. | Methods and systems for producing HIV antigens |
CA1338778C (en) | 1988-06-15 | 1996-12-10 | Richard A. Young | Stress proteins and uses therefor |
WO1990010230A1 (en) | 1989-02-23 | 1990-09-07 | University Of Ottawa | Polypeptide having immunological activity for use as diagnostic reagent and/or vaccine |
US5114844A (en) | 1989-03-14 | 1992-05-19 | Yeda Research And Development Co., Ltd. | Diagnosis and treatment of insulin dependent diabetes mellitus |
CA2063414A1 (en) | 1989-06-19 | 1990-12-20 | Richard A. Young | Vector-mediated genomic insertion and expression of dna in bcg |
GB8919321D0 (en) | 1989-08-25 | 1989-10-11 | Univ London | Treatment of chronic inflammatory conditions |
GB9007194D0 (en) | 1990-03-30 | 1990-05-30 | Wellcome Found | Live vaccines |
US5348945A (en) | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
DK0556248T3 (da) | 1990-11-08 | 1997-10-27 | Univ London | Mycobacterium som adjuvans til antigener |
GB9024320D0 (en) | 1990-11-08 | 1990-12-19 | Univ London | Treatment of uveitis |
GB2251186A (en) | 1990-12-04 | 1992-07-01 | Randall Neal Gatz | Polypeptide for use in treatment of autoimmune disease |
EP0521220A1 (en) | 1991-06-14 | 1993-01-07 | Institut Pasteur | Recombinant immunogenic actinomycetale |
GB9113809D0 (en) | 1991-06-26 | 1991-08-14 | Cancer Res Campaign Tech | Papillomavirus l2 protein |
IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
US5580563A (en) | 1992-05-01 | 1996-12-03 | Tam; James P. | Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof |
GB9211736D0 (en) | 1992-06-03 | 1992-07-15 | Univ Cardiff | Allergic treatment |
IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
US5736146A (en) | 1992-07-30 | 1998-04-07 | Yeda Research And Development Co. Ltd. | Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them |
ATE212378T1 (de) | 1993-06-04 | 2002-02-15 | Whitehead Biomedical Inst | Stressproteine und ihre verwendung |
US5404142A (en) | 1993-08-05 | 1995-04-04 | Analog Devices, Incorporated | Data-directed scrambler for multi-bit noise shaping D/A converters |
DE69434475T2 (de) | 1993-08-11 | 2006-05-18 | Jenner Technologies, Tiburon | Impfstoff gegen prostatakrebs |
US5762939A (en) | 1993-09-13 | 1998-06-09 | Mg-Pmc, Llc | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus |
US5750119A (en) | 1994-01-13 | 1998-05-12 | Mount Sinai School Of Medicine Of The City University Of New York | Immunotherapeutic stress protein-peptide complexes against cancer |
US5997873A (en) | 1994-01-13 | 1999-12-07 | Mount Sinai School Of Medicine Of The City University Of New York | Method of preparation of heat shock protein 70-peptide complexes |
US5961979A (en) | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
IL109790A0 (en) | 1994-05-25 | 1994-08-26 | Yeda Res & Dev | Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines |
GB9419979D0 (en) | 1994-10-04 | 1994-11-16 | Medeva Holdings Bv | Vaccine compositions |
AUPN015794A0 (en) | 1994-12-20 | 1995-01-19 | Csl Limited | Variants of human papilloma virus antigens |
JP3958360B2 (ja) | 1995-02-24 | 2007-08-15 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
HUP9802819A2 (hu) | 1995-08-18 | 1999-03-29 | Sloan-Kettering Institute For Cancer Research | Hősokkfehérje-alapú oltóanyagok és immunterápiák |
US5837251A (en) | 1995-09-13 | 1998-11-17 | Fordham University | Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases |
US5985270A (en) | 1995-09-13 | 1999-11-16 | Fordham University | Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes |
US5935576A (en) | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
WO1997026910A2 (de) | 1996-01-27 | 1997-07-31 | Max-Delbrück-Centrum für Molekulare Medizin | Tumorimpfstoff für die immuntherapie von malignen tumoren |
CZ28899A3 (cs) * | 1996-07-29 | 1999-07-14 | Cantab Pharmaceuticals Research Limited | Polypeptidy použitelné jako imunoterapeutická činidla a způsoby přípravy polypeptidů |
US6130087A (en) | 1996-10-07 | 2000-10-10 | Fordham University | Methods for generating cytotoxic T cells in vitro |
EP0941315B1 (en) | 1996-11-26 | 2006-03-01 | Stressgen Biotechnologies Corporation | Fusion proteins containing stress proteins for inducing immune responses |
US5830464A (en) | 1997-02-07 | 1998-11-03 | Fordham University | Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy |
US6017540A (en) | 1997-02-07 | 2000-01-25 | Fordham University | Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes |
EP1047451A1 (en) | 1997-02-18 | 2000-11-02 | Whitehead Institute For Biomedical Research | Use of heat shock proteins to deliver moieties into cells |
ES2191929T3 (es) * | 1997-08-05 | 2003-09-16 | Stressgen Biotechnologies Corp | Respuestas inmunologicas contra los antigenos pvh estimuladas por composiciones que comprenden un antigeno pvh y una proteina de estres o un vector de expresion capaz de expresar dichas proteinas. |
US6007821A (en) | 1997-10-16 | 1999-12-28 | Fordham University | Method and compositions for the treatment of autoimmune disease using heat shock proteins |
US5948646A (en) | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
GB9727262D0 (en) | 1997-12-24 | 1998-02-25 | Smithkline Beecham Biolog | Vaccine |
CN1248631A (zh) * | 1998-09-24 | 2000-03-29 | 周国庆 | 一种免疫预防和免疫治疗性病和癌症的融合蛋白 |
US6451316B1 (en) | 1998-10-05 | 2002-09-17 | University Of Conneticut Health Center | Methods for generating antigen-reactive T cells in vitro |
US6475490B1 (en) | 1998-10-19 | 2002-11-05 | Fordham University | Compositions and methods for promoting tissue repair using heat shock proteins |
US6497880B1 (en) | 1998-12-08 | 2002-12-24 | Stressgen Biotechnologies Corporation | Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
CA2383213A1 (en) | 1999-09-10 | 2001-03-15 | Fordham University | Methods and compositions for the treatment and prevention of graft rejection using heat shock proteins |
US20010034042A1 (en) | 2000-01-20 | 2001-10-25 | Srivastava Pramod K. | Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents |
WO2001052890A1 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Heat shock/stress protein complexes as vaccines against neurodegenerative disorders |
WO2001052877A1 (en) | 2000-01-21 | 2001-07-26 | University Of Connecticut Health Center | Compositions and methods to treat neurodegenerative disorders |
AU2001229592A1 (en) | 2000-01-21 | 2001-07-31 | University Of Connecticut Health Center | Vaccines against neurodegenerative disorders |
IL153474A0 (en) * | 2000-06-26 | 2003-07-06 | Stressgen Biotechnologies Corp | Human papilloma virus treatment |
-
2001
- 2001-06-26 IL IL15347401A patent/IL153474A0/xx unknown
- 2001-06-26 EP EP01950461A patent/EP1296711B1/en not_active Expired - Lifetime
- 2001-06-26 CZ CZ20024154A patent/CZ20024154A3/cs unknown
- 2001-06-26 KR KR1020087018500A patent/KR20080075560A/ko not_active Application Discontinuation
- 2001-06-26 KR KR1020027017697A patent/KR100919266B1/ko not_active IP Right Cessation
- 2001-06-26 BR BR0111956-7A patent/BR0111956A/pt not_active IP Right Cessation
- 2001-06-26 DE DE60119734T patent/DE60119734T2/de not_active Expired - Fee Related
- 2001-06-26 HU HU0301308A patent/HUP0301308A3/hu unknown
- 2001-06-26 PL PL35993001A patent/PL359930A1/xx not_active Application Discontinuation
- 2001-06-26 AU AU7144901A patent/AU7144901A/xx active Pending
- 2001-06-26 PT PT01950461T patent/PT1296711E/pt unknown
- 2001-06-26 CA CA002413543A patent/CA2413543A1/en not_active Abandoned
- 2001-06-26 WO PCT/US2001/020240 patent/WO2002000242A2/en active IP Right Grant
- 2001-06-26 AT AT01950461T patent/ATE326236T1/de not_active IP Right Cessation
- 2001-06-26 ES ES01950461T patent/ES2263637T3/es not_active Expired - Lifetime
- 2001-06-26 SK SK1836-2002A patent/SK18362002A3/sk not_active Application Discontinuation
- 2001-06-26 NZ NZ523408A patent/NZ523408A/en unknown
- 2001-06-26 MX MXPA02012858A patent/MXPA02012858A/es active IP Right Grant
- 2001-06-26 AU AU2001271449A patent/AU2001271449B2/en not_active Ceased
- 2001-06-26 US US09/891,823 patent/US20020110566A1/en not_active Abandoned
- 2001-06-26 EE EEP200200709A patent/EE200200709A/xx unknown
- 2001-06-26 RU RU2003101965/14A patent/RU2282461C2/ru not_active IP Right Cessation
- 2001-06-26 DK DK01950461T patent/DK1296711T3/da active
- 2001-06-26 JP JP2002505023A patent/JP2004512264A/ja not_active Withdrawn
- 2001-06-26 CN CNB018117724A patent/CN100441223C/zh not_active Expired - Fee Related
-
2002
- 2002-12-16 NO NO20026044A patent/NO20026044L/no not_active Application Discontinuation
- 2002-12-17 ZA ZA200210211A patent/ZA200210211B/en unknown
- 2002-12-19 HR HR20021015A patent/HRP20021015A2/hr not_active Application Discontinuation
-
2003
- 2003-02-13 US US10/365,908 patent/US6797491B2/en not_active Expired - Fee Related
-
2004
- 2004-06-18 US US10/871,138 patent/US7211411B2/en not_active Expired - Fee Related
-
2006
- 2006-08-03 CY CY20061101090T patent/CY1105389T1/el unknown
- 2006-08-09 AU AU2006203436A patent/AU2006203436A1/en not_active Abandoned
-
2007
- 2007-04-26 US US11/796,144 patent/US7754449B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1296711T3 (da) | HPV-E7 til behandling af humant papillomavirus | |
EA200600582A1 (ru) | Способы и композиции для лечения вирусного гепатита с | |
DE60105424D1 (de) | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden | |
MXPA02005639A (es) | Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico. | |
AP1771A (en) | 3'-Prodrugs of 2'-deoxy-?-L-nucleosides. | |
ATE475423T1 (de) | Immunostimulierende polynukleotide sequenzen zur verwendung bei der verhinderung und behandlung von viralen erkrankungen | |
PT933993E (pt) | Compostos de ciclopentano substituidos, uteis como inibidores de neuraminidase | |
DK1292328T3 (da) | Kimære humant papillomvirus- (HPV) - molekyler og deres anvendelse | |
CY1108147T1 (el) | Εμβολιο κατα των σεξουαλικως μεταδιδομενων νοσων | |
DK1255815T3 (da) | Porcint reproduktivt og respiratorisk syndromvirus til fremgangsmåder til anvendelse | |
ATE279940T1 (de) | Behandlung und prävention von helicobacter- infektionen | |
EA200500834A1 (ru) | Вакцина на основе вирусоподобных частиц вируса папилломы человека 16 и вируса папилломы человека 18 l1 | |
HUP9901958A2 (hu) | Sertés reproduktív és respirációs szindróma vakcina | |
AUPQ761200A0 (en) | Compositions and methods for treatment of mucosal infections | |
DE69533067D1 (de) | Hepatis e-virus antigene und dessen verwendungen | |
MXPA03009763A (es) | Vacuna contra el virus de la enfermedad de la fiebre aftosa. | |
NZ512850A (en) | Treatment of papillomavirus infections | |
DE69615685T2 (de) | Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen | |
TR200202169T1 (tr) | Tanı ve tedavide kullanım için pürifiye hepatit C virüsü zarf proteinleri. | |
DE60229126D1 (de) | Pre-s-protein von hepatitis-b-virus (hbv) als adjuvans und komponente eines hbv-impfstoffs | |
ES2195861T3 (es) | Uso de (ir,4s)-4-(6-amino-9h-purin-9-il)-2-ciclopenten-1-metanol en vhb. |